Patents Assigned To Johns Hopkins University

  • U.S. Patent Number 7,576,323
    A point-of-care mass spectrometer system has a sampling system, an ionization component structured to receive a sample for analysis from the sampling system, a
  • U.S. Patent Number 7,557,200
    Improved molecular vaccines comprise nucleic acid vectors that encode a fusion polypeptide that includes polypeptide or peptide physically linked to an antigen. The linked
  • U.S. Patent Number 7,517,680
    Genetically engineered Streptomyces clavuligerus strains with improved capabilities to produce clavulanic acid are provided. The strains are genetically engineered by disrupting newly identified glyceraldehyde-3-phosphate
  • U.S. Patent Number 7,514,579
    The present invention relates to novel boronic chalcone derivatives which are useful as antitumor/anticancer agents. The present compounds, which are inexpensive to synthesize, exhibit
  • U.S. Patent Number 7,508,999
    A fiber optic sensor device for detecting the presence of a chromophoric compound in a biological fluid is disclosed. The fiber optic sensor device
  • U.S. Patent Number 7,494,494
    Featured is an apparatus that places or locates a proximal end portion of a penetrating member in a target area of a body. Such
  • U.S. Patent Number 7,485,113
    Devices and devices for the treatment of the eye are disclosed. Preferred devices of the invention include a piercing member that is inserted into
  • U.S. Patent Number 7,417,156
    In only two steps and in 65% overall yield, natural trioxane artemisinin (I) was converted on gram scale into C-10-carba trioxane dimer (3). This
  • U.S. Patent Number 7,399,830
    Disclosed are nucleotide coding sequences and polypeptide sequences for synaptic activation binding proteins that are characterized by induction in the central nervous system following
  • U.S. Patent Number 7,375,520
    A T2 preparation sequence uses a segmented BIR-4 adiabatic pulse with two substantially equal delays and is insensitive to B1 field variations and can
  • U.S. Patent Number 7,361,412
    Self-propagating formation reactions in nanostructured multilayer foils provide rapid bursts of heat at room temperature and therefore can act as local heat sources to
  • U.S. Patent Number 7,344,887
    This invention is predicated on the present applicants' discovery that nanostructures comprising discrete regions of different composition can be used to deliver to a
  • U.S. Patent Number 7,282,476
    Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific
  • U.S. Patent Number 7,256,182
    The present provides methods and compositions that enable effective delivery of nucleic acids to desired cells, including to a solid organ such as a
  • U.S. Patent Number 7,236,816
    Herein is disclosed a magnetic resonance imaging antenna, including an inner conductor, an outer shield slideably displaceable with respect to the inner conductor, and
  • U.S. Patent Number 7,214,772
    SAF-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SAF-2 polypeptides and
  • U.S. Patent Number 7,192,579
    The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration.
  • U.S. Patent Number 7,185,550
    A fluid sampling device is provided comprising an elongated housing having a longitudinal axis, a plurality of alternating sorbent units and spacer units disposed
  • U.S. Patent Number 7,176,691
    A pulse induction metal detector includes a pulse transmitter coil for generating and transmitting a first electromagnetic signal and a receiver coil for detecting
  • U.S. Patent Number 7,166,585
    The present invention provides novel C24-sulfone analogs of 1α,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors
  • U.S. Patent Number 7,148,706
    An embeddable corrosion rate meter (ECRM) for detecting and measuring corrosion in metal and concrete structures is provided. The system comprises an electrochemical cell
  • U.S. Patent Number 7,138,242
    This invention provides novel libraries of olfactory receptor odorant/ligand-binding domains and methods of making and using them. The invention also provides libraries of vectors
  • U.S. Patent Number 7,118,888
    An effective prophylactic mucosal gene expression vaccine (GXV), made up of a cocktail of at least 4 different plasmid DNAs encoding corresponding RSV antigens,
  • U.S. Patent Number 7,108,704
    A percutaneous thrombolytic device, also referred to herein as a percutaneous mechanical fragmentation catheter system, that includes a wire cage or basket attached to
  • U.S. Patent Number 7,107,824
    A continuous flow centrifuge adapted with an insert of glass beads, sand or the like is used to concentrate cysts of microorganisms such as
  • U.S. Patent Number 7,087,583
    Specific sequences in the human genome are the sites of strong binding of wild-type p53 protein, but not mutant forms of the protein. These
  • U.S. Patent Number 7,078,903
    Disclosed is a method and system for steady state free precession based magnetic resonance thermometry that measures changes in temperature on a pixel by
  • U.S. Patent Number 7,067,659
    A reactive oxygen generating enzyme inhibitor with NO donor bioactivity, e.g., nitrated allopurinol, e.g., 1,5-bis(3-nitrooxypropyyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-one is useful to treat heart failure, stable angina, ischemic
  • U.S. Patent Number 7,060,457
    In one aspect, the present invention features methods for detecting at least one neurological disorder in a patient, the method comprising obtaining a biological
  • U.S. Patent Number 7,045,617
    Protein kinase inhibitors have applications as anti-cancer therapeutic agents and biological tools in cell signalling. Potent and selective bisubstrate inhibitors for the insulin receptor
  • U.S. Patent Number 7,030,219
    A novel costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors
  • U.S. Patent Number 7,030,100
    Several lines of evidence have shown a role for the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway in the development of spinal hyperalgesia.
  • U.S. Patent Number 6,991,856
    Reactive foils and their uses are provided as localized heat sources useful, for example, in ignition, joining and propulsion. An improved reactive foil is
  • U.S. Patent Number 6,991,855
    Reactive foils and their uses are provided as localized heat sources useful, for example, in ignition, joining and propulsion. An improved reactive foil is
  • U.S. Patent Number 6,982,258
    The present invention provides novel 16-ene-C25-oxime and 16-ene-C-25-oxime ether analogs of 1α,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds
  • U.S. Patent Number 6,958,411
    Nordihydroguaiaretic acid derivatives and methods of use thereof for the treatment of tumors.
  • U.S. Patent Number 6,936,639
    Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure
  • U.S. Patent Number 6,918,973
    In accordance with a preferred embodiment of the invention, an alloy or other composite material is provided formed of a bulk metallic glass matrix
  • U.S. Patent Number 6,913,885
    A central role for the gene encoding dopamine beta-hydroxylase in neuropsychiatric disorders is disclosed. Use of single nucleotide polymorphisms in the dopamine beta-hydroxylase gene
  • U.S. Patent Number 6,906,182
    A conjugate of formula A-L-P, in which: A represents a glycosylated/galactosylated peptide that binds to a cell-surface receptor, L represents a bifunctional linker, which
  • U.S. Patent Number 6,892,089
    The present invention relates to a method of measuring motion of an object such as a heart by magnetic resonance imaging. A pulse sequence
  • U.S. Patent Number 6,875,521
    Reactive foils and their uses are provided as localized heat sources useful, for example, in ignition, joining and propulsion. An improved reactive foil is
  • U.S. Patent Number 6,867,288
    The present invention provides methods and compositions for treating cyst formation in PKD1-associated epithelial cells. Such methods encompass administering an isolated human PKD1 gene,
  • U.S. Patent Number 6,863,992
    Reactive foils and their uses are provided as localized heat sources useful, for example, in ignition, joining and propulsion. An improved reactive foil is
  • U.S. Patent Number 6,858,415
    The present invention relates to novel human glycosylation enzyme polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides.
  • U.S. Patent Number 6,855,515
    The present invention provides a method of producing autoantigens, compositions comprising autoantigenic fragments and methods of using autoantigenic fragments in the treatment of a
  • U.S. Patent Number 6,852,709
    The present invention provides biodegradable polymers, polymer compositions, particles composed thereof and methods of using same for the controlled release of a biologically active
  • U.S. Patent Number 6,846,651
    The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence
  • U.S. Patent Number 6,824,551
    A percutaneous thrombolytic device, also referred to herein as a percutaneous mechanical fragmentation catheter system, that includes a wire cage or basket attached to
  • U.S. Patent Number 6,805,972
    The present invention is directed to nanoporous metal membranes and methods of making nanoporous metal membranes from metal leaf. At least a portion of
  • U.S. Patent Number 6,805,876
    Featured are biodegradable polymers comprising repeat units derived from cyclic phosphate monomers and optionally further comprising repeat units derived from lactide or caprolactone monomers.
  • U.S. Patent Number 6,797,466
    The present application describes the complete 1.66-megabase pair genome sequence of an autotrophic archaeon, Methanococcus jannaschii, and its 58- and 16-kilobase pair extrachromosomal elements.
  • U.S. Patent Number 6,774,128
    Disclosed are methods for preventing or treating a gastrointestinal (GI) disorder in a mammal such as a human patient. In one embodiment, the methods
  • U.S. Patent Number 6,771,070
    Featured is a device for detecting electromagnetic signals, more specifically, the magnetic resonance signals from excited nuclei as well as related apparatuses, systems and
  • U.S. Patent Number 6,736,942
    Reactive foils and their uses are provided as localized heat sources useful, for example, in ignition, joining and propulsion. An improved reactive foil is
  • U.S. Patent Number 6,734,173
    The invention provides compositions and methods of vaccination that enhance the potency of DNA vaccines. The immunogenic composition contains a DNA encoding a carboxyterminal
  • U.S. Patent Number 6,723,838
    The present invention features molecules that relate to SYNGAP (Synaptic GTPase Activating Protein), an excitatory synapse protein that has been found to bind synaptic
  • U.S. Patent Number 6,720,830
    A low-power differential optical receiver useful for high-speed optical communication between CMOS chips includes a multi-stage differential amplifier circuit including a first differential transimpedance
  • U.S. Patent Number 6,713,300
    The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration.
  • U.S. Patent Number 6,699,621
    A method of manufacture of an electrode formed from at least one electrically conductive polymer having a lower, polymerization potential than p-doping peak. The
  • U.S. Patent Number 6,692,590
    An alloy is described that is capable of forming a metallic glass at moderate cooling rates and exhibits large plastic flow at ambient temperature.
  • U.S. Patent Number 6,663,690
    Elemental mercury is removed from emissions of coal-fired utilities by the selective photoionization of mercury atoms using ultraviolet light, followed by electrostatic precipitation of
  • U.S. Patent Number 6,637,437
    The invention is directed to the culture of cells, and particularly chondrocytes for purpose of tissue replacement. The cells are cultured on polymer constructs.
  • U.S. Patent Number 6,610,290
    The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for
  • U.S. Patent Number 6,608,108
    Use of nordihydroguaiaretic derivatives to suppress CDC-2 and survivin, stimulate apoptosis, and treat tumors.DescriptionThis application is a continuation in part of U.S. application Ser.
  • U.S. Patent Number 6,596,101
    Preferred embodiments of the invention provide new nanostructured materials and methods for preparing nanostructured materials having increased tensile strength and ductility, increased hardness, and
  • U.S. Patent Number 6,593,095
    The present invention relates to toxins that specifically bind to GPI anchored proteins. More specifically, the present invention encompasses the uses of such toxins
  • U.S. Patent Number 6,590,087
    A whmD gene that controls sporulation in mycobacteria, vectors and transformed cells containing the gene.DescriptionThis invention was developed with support from NIH Grants R29
  • U.S. Patent Number 6,586,464
    Methods for producing novel artemisinin analogs and artemisinin dimers having antimalarial, antiproliferative and antitumor activities are described herein. These novel artemisinin analogs and artemisinin
  • U.S. Patent Number 6,586,241
    The present invention relates to methods for identifying a compound capable of modulating mitochondrial function, comprising contacting a eukaryotic cell with one or more
  • U.S. Patent Number 6,572,629
    A technique is described for reducing the stomach cavity endoscopically, from within the stomach or, in the alternative, from within the peritoneal cavity via
  • U.S. Patent Number 6,569,862
    The present invention relates to methods for modulating calcium sensitivity of cardiac muscle. In preferred aspects, the invention provides methods for enhancing myocardial contractility
  • U.S. Patent Number 6,566,095
    Methods, compositions and articles for blocking transepithelial transmission of HIV with ICAM-1 angonist/antagonists are provided. The ICAM-1 agonist/antagonists block viral transmission at the site
  • U.S. Patent Number 6,551,291
    In preferred aspects, the present invention features a non-traumatic cannula for use in connection with eye surgery, such as retinal tear and/or detachment surgery.
  • U.S. Patent Number 6,546,375
    An apparatus for and method of determining the price of financial derivatives such as options. One preferred embodiment of the invention employs a discretized
  • U.S. Patent Number 6,537,773
    The present invention provides the nucleotide sequence of the entire genome of Mycoplasma genitalium, SEQ ID NO:1. The present invention further provides the sequence
  • U.S. Patent Number 6,534,194
    In accordance with the invention a reactive multilayer foil is fabricated by providing an assembly (stack or multilayer) of reactive layers, inserting the assembly
  • U.S. Patent Number 6,529,331
    A head mounted virtual environment display with high visual resolution and a full field of view is disclosed. The display uses an optical system
  • U.S. Patent Number 6,528,289
    The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence
  • U.S. Patent Number 6,518,568
    A time-of-flight mass spectrometer includes a sample holder for a sample and an ionizer for ionizing the sample to form ions. A first element
  • U.S. Patent Number 6,511,979
    The present invention includes methods for treatment and prophylaxis of conditions associated with lactosylceramide. The methods generally provide for administration to a mammal, particularly
  • U.S. Patent Number 6,509,515
    Provided is a transgenic non-human eukaryotic animal whose germ cells and somatic cells contain the amyloid precursor protein sequence introduced into the animal, or
  • U.S. Patent Number 6,506,581
    The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence
  • U.S. Patent Number 6,503,729
    The present application describes selected polynucleotide sequence from the 1.66-megabase pair genome sequence of an autotrophic archaeon, Methanococcus jannaschii, and its 58- and 16-kilobase
  • U.S. Patent Number 6,494,314
    A unit dose, gas-filled syringe is provided which is filled with gas and packaged in a gas barrier material prior to use to increase
  • U.S. Patent Number 6,476,606
    There is featured a method for parallel spatial encoding MR image data that is frequency-encoded and sensitivity-encoded that includes applying an analytical transform function
  • U.S. Patent Number 6,468,765
    The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence
  • U.S. Patent Number 6,458,838
    4-phenylbutyrate treatment of cells from both X-ALD patients and X-ALD knockout mice results in decreased levels of and increased β-oxidation of very-long-chain fatty acids;
  • U.S. Patent Number 6,458,541
    Methods for diagnosing and treating neuropsychiatric disorders, especially bipolar disorder, and to methods for identifying compounds for use in the diagnosis and treatment of
  • U.S. Patent Number 6,452,065
    The present invention relates to a transgenic non-human animal embryo lacking native presenilin 1 and a transgenic non-human animal having only a non-native presenilin
  • U.S. Patent Number 6,440,706
    The identification of pre-defined mutations expected to be present in a minor fraction of a cell population is important for a variety of basic
  • U.S. Patent Number 6,417,234
    Nordihydroguaiaretic acid derivatives and methods of use thereof for the treatment of tumors.DescriptionThis application continuation-in-part to U.S. application Ser. No. 08/418,594, filed Oct. 15,
  • U.S. Patent Number 6,410,517
    A target-specific gene delivery system is made of enzymatically degradable gelatin and nucleic acids (DNA or RNA) microparticles with a linking moiety or a
  • U.S. Patent Number 6,410,296
    A herpes virus proteinase has been found to be encoded by a member of a family of four nested genes in simian cytomegalovirus. Another
  • U.S. Patent Number 6,407,330
    A solar cell incorporates a light harvesting array that comprises: (a) a first substrate comprising a first electrode; and (b) a layer of light
  • U.S. Patent Number 6,406,902
    A herpes virus proteinase has been found to be encoded by a member of a family of four nested genes in simian cytomegalovirus. Another
  • U.S. Patent Number 6,403,675
    Biodegradable, flowable or flexible polymer compositions are described comprising a polymer having the recurring monomeric units shown in formula I: wherein:each of R and
  • U.S. Patent Number 6,400,979
    A method for performing radiological-image-guided percutaneous surgery with a system which includes a radiological image generating device for generating an image of a target
  • U.S. Patent Number 6,376,471
    The present provides methods and compositions that enable effective delivery of nucleic acids to desired cells, including to a solid organ such as a
  • U.S. Patent Number 6,375,951
    The invention features a non-immunogenic construct for reducing a non-primary antibody response to an epitope of a T-dependent antigen. The construct is free of
  • U.S. Patent Number 6,358,975
    Neutral tissue damage resulting for ischemia and reperfusion injury or neurodegenerative diseases can be prevented by administering therapeutically effective amounts of certain selective inhibitors
  • U.S. Patent Number 6,358,713
    Methods for selecting rRNA variants that catalyze formation of non-standard polymers are described.DescriptionCROSS-REFERENCE TO RELATED APPLICATIONSThis application claims priority from U.S. Provisional Application No.
  • U.S. Patent Number 6,355,467
    It has been found that Pyrococcus furiosus produces several starch hydrolyzing enzymes, both extracellularly and intracellularly, which retain their activity for several hours at
  • U.S. Patent Number 6,355,235
    Certain antibody molecules are so stable and so potent at immobilizing sperm as well as the pathogens for sexually transmitted diseases (STDs) that they
  • U.S. Patent Number 6,337,994
    An electrical impedance probe is provided that includes a surgical needle. In an exemplary embodiment, the probe is a two-part trocar needle designed to
  • U.S. Patent Number 6,335,011
    The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for
  • U.S. Patent Number 6,333,182
    The present invention relates to novel human glycosylation enzyme polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides.
  • U.S. Patent Number 6,325,998
    The use of recombinant adeno-associated virus (AAV) virions for delivery ofDNA molecules to muscle cells and tissue in the treatment of anemia is disclosed.
  • U.S. Patent Number 6,322,797
    Biodegradable terephthalate polymers are described comprising the recurringmonomeric units shown in formula I: [Figure] wherein R is a divalent organic moiety;R' is an aliphatic,
  • U.S. Patent Number 6,309,419
    A tympanic membrane prosthesis is provided that includes, in combination, a generally flat, planar membrane sized to overlay a tear or perforation in the
  • U.S. Patent Number 6,300,131
    A human staufen polypeptide that is associated with telomerase is described. Methods for inhibiting telomerase activity also are described. STATEMENT AS TO FEDERALLY SPONSORED
  • U.S. Patent Number 6,300,059
    A human gene, WAF1, has been identified which is induced by wild-type but not mutant p53 in human brain tumor cells. The gene is
  • U.S. Patent Number 6,297,272
    Methods for producing novel artemisinin analogs and artemisinin dimers having antimalarial, antiproliferative and antitumor activities are described herein. These novel artemisinin analogs and artemisinin
  • U.S. Patent Number 6,291,524
    A method for suppressing undesired viral growth in a host which comprises administering to the host an effective amount of a compound of the
  • U.S. Patent Number 6,287,848
    A monitoring system such as a drug dosage modeling system is disclosed. In preferred embodiments, the system provides mixing without the need for mechanical
  • U.S. Patent Number 6,278,975
    A voice command and control medical care system is provided which comprises a processor having a continuous speech recognition capability. The processor is programmed
  • U.S. Patent Number 6,265,196
    The present invention reveals a method for enzymatically inactivating a target DNA, a method for detecting conformational change in a nucleic acid, and a
  • U.S. Patent Number 6,262,335
    A transgenic non-human eukaryotic animal whose germ cells and somatic cells contain the amyloid precursor protein sequence introduced into the animal, or an ancestor
  • U.S. Patent Number 6,248,078
    The present invention features test systems and methods for detecting a hepatic disorder in a mammal and especially a primate. Preferred use of the
  • U.S. Patent Number 6,228,889
    The present invention includes methods for treatment and prophylaxis of diseases, post-surgical disorders and bacterial infections associated with lactosylceramide. The methods generally provide for
  • U.S. Patent Number 6,204,000
    The isolation and characterization of a metastasis tumor suppressor gene KAI1 is disclosed and diagnostic methods and gene therapy approaches utilizing reagents derived from
  • U.S. Patent Number 6,191,136
    The present invention relates to methods for modulating calcium sensitivityof cardiac muscle. In preferred aspects, the invention provides methods for enhancing myocardial contractility and
  • U.S. Patent Number 6,183,948
    The present invention relates to methods for identifying a compound capable of modulating mitochondrial function, comprising contacting a eukaryotic cell with one or more
  • U.S. Patent Number 6,166,173
    Biodegradable polymers are described comprising the recurring monomeric units shown in formula I or II: wherein X is --O-- or --NR'--, where R' is
  • U.S. Patent Number 6,166,065
    2,3-Dioxabicyclo[3.3.1]nonane derivatives, carrying, at position 4, a sulfur-containing functionality selected from the group consisting of sulfonyl, sulfinyl and sulfenyl, adhered to C(4) vie methylene
  • U.S. Patent Number 6,160,004
    The present invention provides a two-step procedure for the replacement of the pyranose anomeric 10-OH group in dihydroartemisinin by a variety of carbon nucleophiles,
  • U.S. Patent Number 6,156,790
    The present invention provides a two-step procedure for the replacement of the pyranose anomeric 10-OH group in dihydroartemisinin by a variety of carbon nucleophiles,
  • U.S. Patent Number 6,156,346
    A delivery system that releases a diagnostic marker or therapeutic agent in a manner sensitive to the concentration of urease in a physiological compartment,
  • U.S. Patent Number 6,146,845
    SAF-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SAF-2 polypeptides and
  • U.S. Patent Number 6,136,847
    Biologically-active, water soluble, 3-substituted trioxanes of the formula [Figure] wherein R represents a COOH-- substituted aryl group, a substituted or unsubstituted heteroaryl group or
  • U.S. Patent Number 6,100,032
    Two human Smad proteins (Smad3 and Smad4) specifically recognize an identical 8 bp palindromic sequence (GTCTAGAC) (SEQ ID NO: 1). Tandem repeats of this
  • U.S. Patent Number 6,092,898
    The invention provides a sapphire surgical contact lens to view interior structures and regions of an eye as well as methods for making and
  • U.S. Patent Number 6,090,566
    Methods and kits are provided for assessing mutations and/or loss of the p53 gene in human tumors. Both deletion mutations and point mutations in
  • U.S. Patent Number 6,086,876
    The invention includes compositions and methods for selective suppression of IL-12 production in a cell. Methods of treating a human having a disease associated
  • U.S. Patent Number 6,080,726
    A method of treating HSV-2 infection which comprises administering to a host subject to said infection an effective amount of a polynucleotide of the
  • U.S. Patent Number 6,073,759
    A unit dose, gas-filled syringe is provided which is filled with gas and packaged in a gas barrier material prior to use to increase
  • U.S. Patent Number 6,071,717
    The present invention involves isolated nucleic acid encoding human PKD1, and sequences derived therefrom. The invention also encompasses vectors comprising these nucleic acids, host
  • U.S. Patent Number 6,045,786
    Certain antibody molecules are so stable and so potent at immobilizing sperm as well as the pathogens for sexually transmitted diseases (STDs) that they
  • U.S. Patent Number 6,043,088
    This invention provides a novel nucleic acid molecule encoding a prostate/colon tumor suppressor gene product. The means and methods for detecting mutations and/or loss
  • U.S. Patent Number 6,040,173
    Three mammalian proteins are disclosed which are useful in the diagnosis and prognosis of tumors of lymphoid and epithelial origin. The three proteins are
  • U.S. Patent Number 6,034,170
    Fluoropolymers containing a specified ratio of hydrogen to fluorine atoms attached to polymer backbone atoms dissolve in carbon dioxide under relatively mild conditions of
  • U.S. Patent Number 6,027,902
    Impaired TPO-mediated platelet protein tyrosine phosphorylation was consistently observed in patients with polycythemia vera (PV) as well as those with idiopathic myelofibrosis (IMF), in
  • U.S. Patent Number 6,025,511
    A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycosyl phosphatidylinositol (GPI) anchor of said parasite
  • U.S. Patent Number 6,025,337
    A target-specific gene delivery system is made of enzymatically degradable gelatin and nucleic acids (DNA or RNA) microparticles with a linking moiety or a
  • U.S. Patent Number 6,008,318
    A process for making a phosphoester polymer comprising the recurringmonomeric units of formula I: [Figure] wherein: X is --O-- or --NR"--, where R" is
  • U.S. Patent Number 5,955,263
    Specific sequences in the human genome are the sites of strong binding ofwild-type p53 protein, but not mutant forms of the protein. These sequences
  • U.S. Patent Number 5,944,747
    A method of focused phosphene generation through deeper intermediateretinal cellular electrical stimulation to the exclusion of direct ganglion cellular electrical stimulation comprises the steps
  • U.S. Patent Number 5,943,116
    A system for obtaining images of the fundus of an eye includes anillumination device which directs a light beam onto a portion of the
  • U.S. Patent Number 5,932,591
    Novel biologically-active 3-substituted trioxanes of the formula[Figure] wherein R represents a substituted alkyl or aryl group of 1-20, preferably 1-12, carbon atoms, and methods
  • U.S. Patent Number 5,916,794
    The present invention reveals a method for enzymatically inactivating atarget DNA, a method for detecting conformational change in a nucleic acid, and a method
  • U.S. Patent Number 5,908,756
    An nNOS associated protein designated PIN-1 (Protein Inhibitor of nNOS) hasbeen identified. It physically interacts with nNOS and inhibits its activity. Multiple lines of
  • U.S. Patent Number 5,893,873
    A surgical instrument includes a handle having a pair of actuating wingsand a removable instrument tip. The instrument tip is constructed to perform a
  • U.S. Patent Number 5,877,399
    Provided is a transgenic non-human eukaryotic animal whose germ cells andsomatic cells contain the amyloid precursor protein sequence introduced into the animal, or an
  • U.S. Patent Number 5,874,234
    Three mammalian are disclosed which are useful in the diagnosis andprognosis of tumors of lymphoid and epithelial origin. The three proteins are immunologically related
  • U.S. Patent Number 5,866,340
    Over the past decade, it has become clear that tumorigenesis is driven byalterations in genes that control cell growth or cell death. Theoretically, the
  • U.S. Patent Number 5,858,351
    The use of recombinant adeno-associated virus (AAV) virions for delivery ofDNA molecules to muscle cells and tissue is disclosed. The invention allows for the
  • U.S. Patent Number 5,851,775
    The APC tumor suppressor protein binds to β-catenin, a protein recently shown to interact with Tcf/Lef transcription factors. Here, the gene encoding a Tcf
  • U.S. Patent Number 5,846,528
    The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is
  • U.S. Patent Number 5,846,241
    A bipolar electrocautery valvulotome in the form of an elongated catheter having a longitudinal axis, a proximal end for being held and manipulated by
  • U.S. Patent Number 5,846,235
    A cryoprobe instrument for endoscopic use has been provided that permits the delivery of liquid or gaseous cryogens in the form of a spray.
  • U.S. Patent Number 5,840,297
    A genus specific chlamydia vaccine is provided which comprises an anti-idiotype antibody capable of producing in an animal an anti-anti-idiotypic antibody which recognizes a
  • U.S. Patent Number 5,834,185
    Methods of detecting, recognizing or inhibiting or altering expression of a target sequence of a single stranded nucleic acid having any combination of purine
  • U.S. Patent Number 5,807,943
    Neoglycoconjugates and new intermediates for the synthesis thereof are synthesized by use of Endo-β-N-acetylglucosaminidase from Arthrobacter protophormiae (Endo-A) in a medium containing an organic
  • U.S. Patent Number 5,766,191
    A percutaneous thrombolytic device, also referred to herein as a percutaneous mechanical fragmentation catheter system, that includes a wire cage or basket attached to
  • U.S. Patent Number 5,756,676
    Three mammalian are disclosed which are useful in the diagnosis and prognosis of tumors of lymphoid and epithelial origin. The three proteins are immunologically
  • U.S. Patent Number 5,747,537
    A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycosyl phosphatidylinositol (GPI) anchor of said parasite
  • U.S. Patent Number 5,726,018
    Three mammalian proteins are disclosed which are useful in the diagnosis and prognosis of tumors of lymphoid and epithelial origin. The three proteins are
  • U.S. Patent Number 5,707,149
    A method for measuring the heat of reaction resulting from the mixture of a plurality of reagents comprising the steps of providing a first
  • U.S. Patent Number 5,696,195
    Perfluorinated polymers are dissolved in supercritical carbon dioxideand/or sulfur hexafluoride at elevated temperatures and pressures. The solutions are useful for making foams, spun-bonded or
  • U.S. Patent Number 5,658,776
    Adeno-associated virus (AAV) vectors may have utility for gene therapy butheretofore a significant obstacle has been the inability to generate sufficient quantifies of such
  • U.S. Patent Number 5,654,170
    The present invention involves isolated nucleic acid encoding human PKD1,and sequences derived therefrom. The invention also encompasses vectors comprising these nucleic acids, host cells
  • U.S. Patent Number 5,653,229
    A new type of airway, the cuffed oro-pharyngeal airway (COPA), isdescribed, which may be used as a less cumbersome alternative to face mask/oral airway
  • U.S. Patent Number 5,616,463
    The dependence of ionizing radiation-induced GADD45 mRNA expression on thepresence of functional p53 in mammalian cells is disclosed. First and second oligonucleotide sequences are
  • U.S. Patent Number 5,593,439
    A device and method to lateralize, or alternatively medialize, the vocalcord is described that is adjustable so that the final position of the vocal
  • U.S. Patent Number 5,591,226
    A percutaneous stent-graft is disclosed for restoring blood flow betweenvessels. The stent-graft has a body implantable device and first and second peel-away retaining elements.
  • U.S. Patent Number 5,554,155
    A multi-function pick-manipulator device that provides the functions of avitreoretinal pick, fiberoptic illumination, and irrigation/aspiration. The manipulator may also function as a bipolar diathermy
  • U.S. Patent Number 5,539,132
    Novel compounds for use in inhibiting fatty acid synthesis are disclosed.The compounds can be used for the treatment of tumors or microbial infections. This
  • U.S. Patent Number 5,496,830
    Camptothecin compounds are effective inhibitors of hemoflagellate growthand are useful in treating leishmaniasis and trypanosomiasis in livestock, other domestic animals and humans. BACKGROUND OF
  • U.S. Patent Number 5,477,144
    A method for removing image artifacts in MRI created when data acquisitionis synchronized to a physiological and therefore uneven intervals. The method simultaneously records
  • U.S. Patent Number 5,358,711
    In vivo and in vitro methods are taught for stimulating the differentiationof stem cells using certain bryostatins. Stem cells can be induced to form
  • U.S. Patent Number 5,192,551
    The binding of neutral glycolipid GA1 (asialo-GM1) to a broad spectrum ofenteric viruses is taught. The glycolipid can be used to pass through the
  • U.S. Patent Number 5,127,032
    A multi-directional x-ray imager for use with an isocentric therapy x-raymachine having a rotatable x-ray source. The imager has a fluorescence screen which emits
  • U.S. Patent Number 5,010,892
    A body lumen measuring instrument for insertion into a body passageway suchas a bronchial tube or the like in order to determine the interior
  • U.S. Patent Number 5,003,982
    The dynamic indentation system cyclically indents a test material for thepurpose of determining mechanical properties that cannot be measured directly, such as in-plane wall
  • U.S. Patent Number 4,953,554
    A magnetic resonance imaging (MRI) method imposes void planes on tissue tobe imaged, which may form a grid pattern of lines which, when later
  • U.S. Patent Number 4,890,313
    An x-ray imager system of the type that indicates alignment of patienttreatment field with x-ray field, using fluorescence screen and imaging sensor, has a
  • U.S. Patent Number 4,772,791
    The effectiveness of drugs and substances that affect brain chemistry canbe efficiently and relatively inexpensively monitored. Radioactive tracer substances comprising a ligand that binds
  • U.S. Patent Number 4,712,561
    The effectiveness of drugs and substances that affect brain chemistry canbe efficiently and relatively inexpensively monitored. Radioactive tracer substances comprising a ligand that binds
  • U.S. Patent Number 6,387,640
    The present invention relates to identification of the consensus sequence phosphorylated by ATM kinase. This, in turn, permitted identification of ATM kinase target proteins,
  • U.S. Patent Number 6,348,311
    The present invention relates to identification of the consensus sequence phosphorylated by ATM kinase. This, in turn, permitted identification of ATM kinase target proteins,
Disclaimer: data is provided as-is from the United States Patent and Trademark Office, modified for presentation purposes only.